CXCL8 and myocardial infarction: Our results suggest that sIL-2R combined with IL-8 may be a helpful biomarker for identifying the increased risk of new cardiovascular events in MI patients and IL-2 and IL-8 would be promising therapeutic targets for anti-inflammatory therapy.